1. AB0765 Secukinumab provides sustained improvement in function, quality of life and fatigue over 2 years in patients who achieved disease activity index for psoriatic arthritis (DAPSA) remission. (15th June 2017) Authors: Smolen, JS; McInnes, IB; Gossec, L; Strand, V; Pricop, L; Fox, T; Jugl, S; Gaillez, C Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 1322 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AB0766 Secukinumab provides sustained remission and low disease activity related to disease activity index for psoriatic arthritis (DAPSA): 2 year results from the future 2 study. (15th June 2017) Authors: Smolen, JS; McInnes, IB; Kvien, TK; Pricop, L; Fox, T; Rasouliyan, L; Jugl, S; Gaillez, C Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 1323 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. AB0772 Secukinumab provides sustained improvement in function, quality of life and fatigue over 2 years in patients who achieved low disease activity related to psoriatic arthritis disease activity score (PASDAS). (15th June 2017) Authors: Coates, LC; Kvien, TK; Nash, P; Gossec, L; Strand, V; Pricop, L; Rasouliyan, L; Ding, K; Jugl, S; Gaillez, C Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 1326 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. AB0780 Secukinumab sustains individual clinical responses over time in patients with psoriatic arthritis: 2-year results from a phase 3 trial, future 2. (15th June 2017) Authors: Emery, P; McInnes, IB; Mease, PJ; Schiff, M; Pricop, L; Shen, S; Wang, Z; Gaillez, C Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 1329 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. FRI0494 Secukinumab provides rapid and sustained pain relief in psoriatic arthritis: 2-year results from the future 2 study. (15th June 2017) Authors: McInnes, IB; Mease, PJ; Schett, G; Kirkham, B; Strand, V; Williams, N; Fox, T; Pricop, L; Jugl, S; Gandhi, KK Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 675 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. FRI0521 Secukinumab provides sustained improvements in work productivity and health related quality of life in patients with active psoriatic arthritis: 2-year results from future 1 and future 2. (15th June 2017) Authors: Strand, V; FitzGerald, O; Coates, LC; Walsh, JA; Cañete, JD; Bhosekar, V; Pricop, L; Gandhi, K; Jugl, S Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 688 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. OP0222 Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 104 weeks results from a phase 3 trial, future 2. (15th June 2017) Authors: McInnes, IB; Mease, PJ; Ritchlin, C; Rahman, P; Gottlieb, A; Kirkham, B; Kajekar, R; Delicha, EM; Pricop, L; Mpofu, S Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 145 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. SAT0463 Secukinumab provides sustained reduction in fatigue in patients with active psoriatic arthritis through 3 years: long-term data from the future 1 and future 2 studies. (15th June 2017) Authors: Gossec, L; Kvien, TK; Conaghan, PG; Østergaard, M; Gladman, D; Mease, P; Rasouliyan, L; Pricop, L; Gaillez, C; Jugl, S Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 949 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. SAT0470 Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 3-year efficacy and safety results from phase 3 future 1 trial. (15th June 2017) Authors: Mease, PJ; Kavanaugh, A; Reimold, A; Tahir, H; Rech, J; Hall, S; Geusens, P; Pascale, P; Delicha, EM; Pricop, L; Mpofu, S Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 952 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. SAT0480 Comparative effectiveness of secukinumab and infliximab in psoriatic arthritis assessed by matching-adjusted indirect comparison using pivotal phase 3 clinical trial data. (15th June 2017) Authors: Strand, V; McInnes, I; Mease, P; Choy, E; Nash, P; Thom, H; Kalyvas, C; Gandhi, K; Pricop, L; Jugl, S Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 957 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗